EASL 2012: Simeprevir (TMC435) Improves Response Rates for Difficult-to-Treat Hepatitis C Patients
- Details
- Category: HCV Treatment
- Published on Monday, 23 April 2012 00:00
- Written by Liz Highleyman
A combination of simeprevir -- better known as TMC435 -- plus pegylated interferon and ribavirin raised cure rates for genotype 1 hepatitis C patients who did not respond to previous treatment, according to a study presented at the 47th International Liver Congress (EASL 2012) last week in Barcelona.
EASL 2012: Telaprevir and Boceprevir Effective but Cause Serious Side Effects in Patients With Cirrhosis
- Details
- Category: HCV Treatment
- Published on Saturday, 21 April 2012 00:00
- Written by Keith Alcorn and Michael Carter
A real-world study of recently approved hepatitis C protease inhibitors in the group of patients who have been told they should not wait for newer, experimental antivirals has shown a much higher rate of serious adverse events and treatment discontinuations than in clinical trials, Christophe Hézode reported on behalf of the French Compassionate Use of Protease Inhibitors in Cirrhotics (CUPIC) cohort study at the 47th International Liver Congress (EASL 2012) in Barcelona on Thursday.
EASL 2012: GS-7977, Daclatasvir, and Asunaprevir Look Good in Interferon-Free Regimens for Hepatitis C
- Details
- Category: HCV Treatment
- Published on Friday, 20 April 2012 00:00
- Written by Liz Highleyman
Most previously untreated people with chronic hepatitis C virus (HCV) infection achieved an early cure with an all-oral combination of the HCV NS5A replication complex inhibitor daclatasvir (formerly BMS-790052) plus the nucleotide NS5B polymerase inhibitor GS-7977, researchers reported this week at the 47th International Liver Congress (EASL 2012) in Barcelona. Another study confirmed that daclatasvir plus the HCV protease inhibitor asunaprevir (formerly BMS-650032) produces a long-term cure for a large proportion of difficult-to-treat patients.
EASL 2012: Entecavir plus Tenofovir for Hepatitis B Patients with Prior Treatment Failure
- Details
- Category: HBV Treatment
- Published on Friday, 20 April 2012 00:00
- Written by Liz Highleyman
A combination of entecavir (Baraclude) plus tenofovir (Viread) resulted in hepatitis B virus (HBV) suppression in a majority of patients who previously experienced treatment failure, according to a study presented at the 47th Annual Meeting of the European Association for the Study of the Liver (EASL 2012) this week in Barcelona.
EASL 2012: International Liver Congress Focuses on Hepatitis C Treatment, Metabolic Liver Disease
- Details
- Category: HCV Treatment
- Published on Friday, 20 April 2012 00:00
- Written by Liz Highleyman
The 47th Annual Meeting of the European Association for the Study of the Liver (EASL 2012) brought together more than 9000 participants this week in Barcelona to discuss the latest research in the field of liver disease.
This year's International Liver Congress is the largest to date, largely reflecting an increased interest in hepatitis C treatment spurred by the development of direct-acting antiviral (DAA) agents.
Web Design and Development by